Quantcast
Last updated on April 23, 2014 at 1:22 EDT

Neuromonics Names Eula Adams CEO

November 19, 2013

Medical device company develops, manufactures products for tinnitus relief

WESTMINSTER, Colo. (PRWEB) November 19, 2013

Neuromonics, Inc., manufacturer and distributor of clinically proven tinnitus treatment devices, has named Eula Adams CEO.

“Eula Adams brings a strong international business base to Neuromonics, with a wealth of financial and organizational experience,” says Ron West, chairman of the board of directors for Neuromonics. “This step can have significant impact on the company’s customers and employees, as well as the audiology industry.”

With nearly 40 years of experience in the financial accounting, financial services and technology industries, Adams has most recently served as president of Denver-based Xcore Corporation. The company designs, assembles and markets a line of low-cost, low-maintenance and low-energy netbooks, keyboard and touch-pad computing devices for global distribution.

Previously, Adams served as senior vice president of storage sales and services for Sun Microsystems, and as president and senior vice president of First Data Corporation, working in Denver. Within First Data, he held the positions of president of Merchant Services, president of Card Issuer Services and president of Teleservices. He also was chief operating officer of Western Union, later acquired by First Data. Earlier in his career, the new CEO spent 19 years with Deloitte, in the greater Atlanta area and in New York City. He was partner in charge of the Atlanta office audit group.

Adams holds a Bachelor of Science degree from Morris Brown College (Atlanta) and a Master of Business Administration degree from Harvard University. He is a licensed certified public accountant in the state of Colorado.

“I am excited to be part of the company’s growth, nationally and internationally,” says Adams. “This is a tremendous opportunity to be a vital part of the medical device and bioscience community, and to chance to help make a difference, with Neuromonics products and treatments, in the lives of those suffering from tinnitus.”

Neuromonics’ FDA-cleared devices and treatments help indiviudals with tinnitus, the condition described as ringing in the ears when no external sounds are present. According to the American Tinnitus Association, more than 50 million people in the United States suffer from the condition. Usually brought on by exposure to loud noise, the problem is especially significant in the military, with more than 34 percent of returning veterans from Iraq and Afghanistan suffering from the condition.

Neuromonics, Inc. (http://www.neuromonics.com)

Based in Westminster, Colo., Neuromonics, Inc., manufactures and distributes clinically proven, FDA-cleared medical devices to treat tinnitus. The Sanctuary provides situational relief for those suffering from mild to moderate tinnitus. The patented and clinically proven Oasis, working the Neuromonics Tinnitus Treatment, provides long-term significant relief for those with severe tinnitus. With research and development beginning in the early 1990s, Neuromonics has helped thousands of tinnitus sufferers improve their quality of life and overcome the daily life challenges associated with tinnitus. Neuromonics’ tinnitus treatments have been featured on national news media including “The Doctors” and CNN.

(end)

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/11/prweb11341526.htm


Source: prweb